DIMA BIOTECH LTD (DIMABIO) focuses exclusively on the pre-clinical research market of Immune Oncology. Currently, we offer functional proteins and recombinant monoclonal antibodies. Our proprietary DimAb™ technology platform can directly clone IgG gene from immunized animal, which is a technology breakthrough in monoclonal antibody development.

All DIMABIOs protein products were manufactured by using mammalian cell expression system. To analyze the function of DIMABIOs proteins, we evaluated them by paired binding test between native ligand-receptor and or the binding capacity to the therapeutic antibodies. For DimAb™ recombinant monoclonal antibodies, we focus mainly on identifying clones with flow and blocking activity.